FDA Approved: REZUROCK — Supplemental Application (Kadmon Pharmaceuticals, LLC)

View source ↗

Summary

The FDA approved a supplemental NDA for REZUROCK (belumosudil) from Kadmon Pharmaceuticals, LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• REZUROCK (belumosudil)

Snippet

SUPPL AP for REZUROCK (BELUMOSUDIL)